Sodium Copper Chlorophyllin
Phase 2Small molecule
Sodium Copper Chlorophyllin is one of 23 small molecule programs targeting Oral Mucositis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Oral Mucositis
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Alka-Seltzer
AAbbott
Approved
Levaquin
WWim Janssens
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Mycostatin
GGood Molecules, LLC
Approved
Betadine
BBecton, Dickinson and Company
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Catapres
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sodium Copper Chlorophyllin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTata Memorial Centre